<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CISATRACURIUM - cisatracurium besylate injection, solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Cisatracurium Besylate Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b1a5e30c-9c40-44de-a270-3e628db7df0e"></a><a name="section-1"></a><p></p>
<p class="First">Rx only</p>
<p>This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. </p>
<p><span class="Bold">NOT FOR USE IN NEONATES</span></p>
<p><span class="Bold">CONTAINS BENZYL ALCOHOL</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="d0ca388b-de3e-434e-ba2c-944f7db5a4fa"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Cisatracurium Besylate Injection is a nondepolarizing skeletal muscle relaxant for intravenous administration.  Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.  Cisatracurium besylate is one of 10 isomers of atracurium besylate and constitutes approximately 15% of that mixture.  Cisatracurium besylate is [1<span class="Italics"><span class="Italics">R</span></span> -[1α,2α(1'<span class="Italics"><span class="Italics">R</span></span>*,2'<span class="Italics"><span class="Italics">R</span></span>*)]]-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] dibenzenesulfonate.  The molecular formula of the cisatracurium parent bis-cation is C<span class="Sub">53</span>H<span class="Sub">72</span>N<span class="Sub">2</span>O<span class="Sub">12</span> and the molecular weight is 929.2.  The molecular formula of cisatracurium as the besylate salt is C<span class="Sub">65</span>H<span class="Sub">82</span>N<span class="Sub">2</span>O<span class="Sub">18</span>S<span class="Sub">2 </span>and the molecular weight is 1243.50.</p>
<p>The structural formula of cisatracurium besylate is:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cisa-struct.jpg"> </p>
<p>The log of the partition coefficient of cisatracurium besylate is -2.12 in a 1-octanol/distilled water system at 25°C.</p>
<p>Cisatracurium Besylate Injection is a sterile, non-pyrogenic aqueous solution provided in 5 mL, 10 mL, and 20 mL vials.  The pH is adjusted to 3.25 to 3.65 with benzenesulfonic acid.  The 5 mL and 10 mL vials each contain cisatracurium besylate, equivalent to 2 mg/mL cisatracurium.  The 20 mL vial, <span class="Bold">intended for ICU use only,</span> contains cisatracurium besylate, equivalent to 10 mg/mL cisatracurium.  The 10 mL vial, intended for multiple dose use, contains 0.9% benzyl alcohol as a preservative.  The 5 mL and 20 mL vials are single use vials and do not contain benzyl alcohol.</p>
<p>Cisatracurium besylate slowly loses potency with time at a rate of approximately 5% per year under refrigeration (5°C).  Cisatracurium should be refrigerated at 2° to 8°C (36° to 46°F) in the carton to preserve potency.  The rate of loss in potency increases to approximately 5% per <span class="Italics"><span class="Italics">month</span></span> at 25°C (77°F).  Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use cisatracurium within 21 days, even if rerefrigerated.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f06a906f-80e7-40bf-a494-81eb1b8a5edf"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Cisatracurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in block of neuromuscular transmission.  This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="f03f5a35-950f-44a1-be85-e793082dc6ef"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">The neuromuscular blocking potency of cisatracurium is approximately threefold that of atracurium besylate.  The time to maximum block is up to 2 minutes longer for equipotent doses of cisatracurium compared to atracurium besylate.  The clinically effective duration of action and rate of spontaneous recovery from equipotent doses of cisatracurium and atracurium besylate are similar. </p>
<br><p>The average ED<span class="Sub">95</span> (dose required to produce 95% suppression of the adductor pollicis <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitch</span> response to ulnar nerve stimulation) of cisatracurium is 0.05 mg/kg (range: 0.048 to 0.053) in adults receiving opioid/nitrous oxide/oxygen anesthesia.  For comparison, the average ED<span class="Sub">95</span> for atracurium when also expressed as the parent bis-cation is 0.17 mg/kg under similar anesthetic conditions. </p>
<br><p>The pharmacodynamics of 2 x ED<span class="Sub">95</span> to 8 x ED<span class="Sub">95</span> doses of cisatracurium administered over 5 to 10 seconds during opioid/nitrous oxide/oxygen anesthesia are summarized in Table 1.  When the dose is doubled, the clinically effective duration of block increases by approximately 25 minutes.  Once recovery begins, the rate of recovery is independent of dose. </p>
<br><p>Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses, and decrease the average infusion rate requirement of cisatracurium.  The magnitude of these effects may depend on the duration of administration of the volatile agents.  Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of cisatracurium and therefore, no adjustment to the initial dose should be necessary when cisatracurium is administered shortly after initiation of volatile agents.  In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of cisatracurium may be necessary.  The average infusion rate requirement may be decreased by as much as 30% to 40%. </p>
<br><p>The onset, duration of action, and recovery profiles of cisatracurium during propofol/oxygen or propofol/nitrous oxide/oxygen anesthesia are similar to those during opioid/nitrous oxide/oxygen anesthesia. </p>
<br><p><span class="Bold"><span class="Italics"> </span>Table 1. Pharmacodynamic Dose Response* of Cisatracurium Besylate Injection During Opioid/Nitrous Oxide/Oxygen Anesthesia</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="8" valign="top"> <br><span class="Bold">Time to Spontaneous Recovery</span><br> <br><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Initial Dose of Cisatracurium (mg/kg)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Time to 90% Block (min)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Time to Maximum Block (min)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">5% Recovery (min)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">25% Recovery<span class="Sup">†  </span>(min)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">95% Recovery (min)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">T<span class="Sub">4</span>:T<span class="Sub">1 </span>Ratio<span class="Sup">‡</span>  ≥ 70% (min)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">25% to 75% Recovery Index (min)</span><br> <br><br><span class="Italics"></span>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="8" valign="top"> <br><span class="Bold">Adults</span><br> <br><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.1<br> <br>(2 x ED<span class="Sub">95</span>) <br><br>(n<span class="Sup">§</span>=98) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.3<br> <br>(1 to 8.7) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>5<br> <br>(1.2 to 17.2) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>33<br> <br>(15 to 51) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>42<br> <br>(22 to 63) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>64<br> <br>(25 to 93) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>64<br> <br>(32 to 91) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>13<br> <br>(5 to 30) <br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.15||<br> <br>(3 x ED<span class="Sub">95</span>) <br><br>(n=39) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.6<br> <br>(1 to 4.4) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.5<br> <br>(1.6 to 6.8) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>46<br> <br>(28 to 65) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>55<br> <br>(44 to 74) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>76<br> <br>(60 to 103) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>75<br> <br>(63 to 98) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>13<br> <br>(11 to 16) <br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.2<br> <br>(4 x ED<span class="Sub">95</span>) <br><br>(n=30) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.4<br> <br>(1.5 to 4.5) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.9<br> <br>(1.9 to 5.2) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>59<br> <br>(31 to 103) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>65<br> <br>(43 to 103) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>81<br> <br>(53 to 114) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>85<br> <br>(55 to 114) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>12<br> <br>(2 to 30) <br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.25<br> <br>(5 x ED<span class="Sub">95</span>) <br><br>(n=15) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.6<br> <br>(0.8 to 3.3) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2<br> <br>(1.2 to 3.7) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>70<br> <br>(58 to 85) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>78<br> <br>(66 to 86) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>91<br> <br>(76 to 109) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>97<br> <br>(82 to 113) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>8<br> <br>(5 to 12) <br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.4<br> <br>(8 x ED<span class="Sub">95</span>) <br><br>(n=15) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.5<br> <br>(1.3 to 1.8) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.9<br> <br>(1.4 to 2.3) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>83<br> <br>(37 to 103) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>91<br> <br>(59 to 107) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>121<br> <br>(110 to 134) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>126<br> <br>(115 to 137) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>14<br> <br>(10 to 18) <br><br><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="8" valign="top"> <br><span class="Bold">Infants (1 to 23 mos.)</span><br> <br><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.15**<br> <br>(n=18 to 26) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.5<br> <br>(0.7 to 3.2) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2<br> <br>(1.3 to 4.3) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>36<br> <br>(28 to 50) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>43<br> <br>(34 to 58) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>64<br> <br>(54 to 84) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>59<br> <br>(49 to 76) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>11.3<br> <br>(7.3 to 18.3) <br><br><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="8" valign="top"> <br><span class="Bold">Children (2 to12 years)</span><br> <br><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.08¶<br> <br>(2 x ED<span class="Sub">95</span>) <br><br>(n=60) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.2<br> <br>(1.2 to 6.8) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3.3<br> <br>(1.7 to 9.7) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>22<br> <br>(11 to 38) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29<br> <br>(20 to 46) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>52<br> <br>(37 to 64) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>50<br> <br>(37 to 62) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>11<br> <br>(7 to 15) <br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.1<br> <br>(n=16) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.7<br> <br>(1.3 to 2.7) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.8<br> <br>(1.8 to 6.7) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>21<br> <br>(13 to 31) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>28<br> <br>(21 to 38) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>46<br> <br>(37 to 58) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>44<br> <br>(36 to 58) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>10<br> <br>(7 to 12) <br><br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> <br>0.15**<br> <br>(n=23 to 24) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.1<br> <br>(1.3 to 2.8) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3<br> <br>(1.5 to 8) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29<br> <br>(19 to 38) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>36<br> <br>(29 to 46) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>55<br> <br>(45 to 72) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>54<br> <br>(44 to 66) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>10.6<br> <br>(8.5 to 17.7) <br><br><br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">*</span> Values shown are medians of means from individual studies.  Values in parentheses are ranges of individual patient values. </p>
<br><p><span class="Sup">†</span> Clinically effective duration of block. </p>
<br><p><span class="Sup">‡ </span>Train-of-four ratio. </p>
<br><p><span class="Sup">§</span> n=the number of patients with Time to Maximum Block data. </p>
<br><p><span class="Sup">||</span> Propofol anesthesia. </p>
<br><p> <span class="Sup">¶</span> Halothane anesthesia. </p>
<br><p><span class="Sup">**</span> Thiopentone, alfentanil, N<span class="Sub">2</span>O/O<span class="Sub">2</span> anesthesia. </p>
<br><p>When administered during the induction of adequate anesthesia using propofol, nitrous oxide/oxygen, and co-induction agents (e.g., fentanyl and midazolam), GOOD or EXCELLENT conditions for tracheal intubation occurred in 96/102 (94%) patients in 1.5 to 2 minutes following 0.15 mg/kg cisatracurium and in 97/110 (88%) patients in 1.5 minutes following 0.2 mg/kg cisatracurium. </p>
<br><p>In one intubation study during thiopental anesthesia in which fentanyl and midazolam were administered two minutes prior to induction, intubation conditions were assessed at 120 seconds.  Table 2 displays these results in this study of 51 patients. </p>
<br><p><span class="Bold">Table 2. Study of Tracheal Intubation Comparing Two Doses of Cisatracurium (Thiopental Anesthesia)</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Intubating Conditions at 120 seconds</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">3 x ED</span><span class="Bold"><span class="Sub">95</span></span><br> <br><span class="Bold">0.15 mg/kg </span><br><br><span class="Bold">n = 26</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">4 x ED</span><span class="Bold"><span class="Sub">95</span></span><br> <br><span class="Bold">0.2 mg/kg </span><br><br><span class="Bold"> n = 25</span><br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Excellent and Good</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>23/26<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>24/25<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>88%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>96%<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   95% CI<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>76, 100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>88, 100<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Excellent</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>8/26<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>15/26<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>31%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>60%<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Good</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>15/26<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>9/25<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>58%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>36%<br> <br><br>
</td>
</tr>
</tbody></table>
<p>While GOOD or EXCELLENT intubation conditions were achieved in the majority of patients in this setting, EXCELLENT intubation conditions were more frequently achieved with the 0.2 mg/kg dose (60%) than the 0.15 mg/kg dose (31%) when intubation was attempted 2 minutes following cisatracurium. </p>
<br><p>A second study evaluated intubation conditions after 3 and 4 x ED<span class="Sub">95</span> (0.15 mg/kg and 0.2 mg/kg) following induction with fentanyl and midazolam and either thiopental or propofol anesthesia.  This study compared intubation conditions produced by these doses of cisatracurium after 1.5 minutes.  Table 3 displays these results. </p>
<br><p><span class="Bold">Table 3. Study of Tracheal Intubation Comparing Three Doses of Cisatracurium (Thiopental or Propofol Anesthesia)</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Intubating Conditions at 90 seconds</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">3 x ED<span class="Sub">95</span></span><br> <br><span class="Bold">0.15 mg/kg</span><br><br><span class="Bold">Propofol</span><br><br><span class="Bold">n = 31</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">3 x ED<span class="Sub">95</span></span><br> <br><span class="Bold">0.15 mg/kg</span><br><br><span class="Bold">Thiopental</span><br><br><span class="Bold">n = 31</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">4 x ED<span class="Sub">95</span></span><br> <br><span class="Bold">0.2 mg/kg</span><br><br><span class="Bold">Propofol</span><br><br><span class="Bold">n = 30</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">4 x ED<span class="Sub">95</span></span><br> <br><span class="Bold">0.2 mg/kg</span><br><br><span class="Bold">Thiopental</span><br><br><span class="Bold">n = 28</span><br><br><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="5" valign="top">
<span class="Bold">Excellent and Good</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29/31<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>28/31<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>28/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>27/28<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>94%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>90%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>93%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>96%<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  95% CI<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>85, 100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>80, 100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>84, 100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>90, 100<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Excellent</span><br>
</td>
<td class="Rrule" align="center" colspan="4" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>18/31<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>17/31<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>22/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>16/28<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>58%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>55%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>70%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>57%<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Good</span><br>
</td>
<td class="Rrule" align="center" colspan="4" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>11/31<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>11/31<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>6/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>11/28<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>35%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>35%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>20%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>39%<br> <br><br>
</td>
</tr>
</tbody></table>
<p>EXCELLENT intubation conditions were more frequently observed with the 0.2 mg/kg dose when intubation was attempted 1.5 minutes following cisatracurium. </p>
<br><p>A third study in pediatric patients (ages 1 month to 12 years) evaluated intubation conditions at 120 seconds after 0.15 mg/kg cisatracurium following induction with either halothane (with halothane/nitrous oxide/oxygen maintenance) or thiopentone and fentanyl (with thiopentone/fentanyl nitrous oxide/oxygen maintenance).  The results are summarized in Table 4. </p>
<br><p><span class="Bold">Table 4. Study of Tracheal Intubation for Pediatrics Stratified by Age Group (0.15 mg/kg Cisatracurium with Halothane or Thiopentone/Fentanyl Anesthesia)</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"><br></td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">Cisatracurium 0.15 mg/kg</span><br> <br><span class="Bold">1 to 11 mo.</span><br><br><span class="Bold">n=30</span><br><br><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">Cisatracurium 0.15 mg/kg </span><br> <br><span class="Bold"> 1 to 4 years</span><br><br><span class="Bold">n=31</span><br><br><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"> <br><span class="Bold">Cisatracurium 0.15 mg/kg</span><br> <br><span class="Bold">5 to 12 years</span><br><br><span class="Bold">n=30</span><br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Intubating Conditions at 120 seconds**</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Halothane Anesthesia</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Thiopentone/Fentanyl Anesthesia</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Halothane Anesthesia</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Thiopentone/Fentanyl Anesthesia</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Halothane Anesthesia</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Thiopentone/Fentanyl Anesthesia</span><br> <br><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="7" valign="top">
<span class="Bold">Excellent and Good</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>30/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>30/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>26/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29/30<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>100%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>100%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>97%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>87%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>97%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>97%<br> <br><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="7" valign="top">
<span class="Bold"><span class="Italics">Excellent</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>30/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>25/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>27/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>19/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>22/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>21/30<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>100%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>83%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>90%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>63%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>73%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>70%<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="Italics">Good</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>5/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>7/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>7/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>8/30<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>17%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>7%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>23%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>23%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>27%<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold"><span class="Italics">Poor</span></span><br>
</td>
<td class="Rrule" align="center" colspan="4" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">  Proportion<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1/30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1/30<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">  Percent<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>13%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3%<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3%<br> <br><br>
</td>
</tr>
</tbody></table>
<p>**<span class="Bold"> Excellent:</span> Easy passage of the tube without <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>.  Vocal cords relaxed and abducted. </p>
<br><p><span class="Bold">Good:</span> Passage of tube with slight <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and/or bucking.  Vocal cords relaxed and abducted. </p>
<br><p><span class="Bold">Poor:</span> Passage of tube with moderate <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and/or bucking.  Vocal cords moderately adducted. </p>
<br><p>Response of patient requires adjustment of ventilation pressure and/or rate. </p>
<br><p>EXCELLENT or GOOD intubating conditions were produced 120 seconds following 0.15 mg/kg cisatracurium in 88/90 (98%) of patients induced with halothane and in 85/90 (94%) of patients induced with thiopentone and fentanyl.  There were no patients for whom intubation was not possible, but there were 7/120 patients ages 1 to 12 years for whom intubating conditions were described as poor. </p>
<br><p>Repeated administration of maintenance doses or a continuous infusion of cisatracurium for up to 3 hours is not associated with development of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> or cumulative neuromuscular blocking effects.  The time needed to recover from successive maintenance doses does not change with the number of doses administered as long as partial recovery is allowed to occur between doses.  Maintenance doses can therefore be administered at relatively regular intervals with predictable results.  The rate of spontaneous recovery of neuromuscular function after infusion is independent of the duration of infusion and comparable to the rate of recovery following initial doses (Table 1). </p>
<br><p>Long-term infusion (up to 6 days) of cisatracurium during mechanical ventilation in the ICU has been evaluated in two studies.  In a randomized, double-blind study using presence of a single twitch during train-of-four (TOF) monitoring to regulate dosage, patients treated with cisatracurium (n = 19) recovered neuromuscular function (T<span class="Sub">4</span>:T<span class="Sub">1</span> ratio ≥ 70%) following termination of infusion in approximately 55 minutes (range: 20 to 270) whereas those treated with vecuronium (n = 12) recovered in 178 minutes (range: 40 minutes to 33 hours).  In another study comparing cisatracurium and atracurium, patients recovered neuromuscular function in approximately 50 minutes for both cisatracurium (range: 20 to 175; n = 34) and atracurium (range: 35 to 85; n = 15). </p>
<br><p>The neuromuscular block produced by cisatracurium is readily antagonized by anticholinesterase agents once recovery has started.  As with other non-depolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. </p>
<br><p>In children (2 to 12 years) cisatracurium has a lower ED<span class="Sub">95</span> than in adults (0.04 mg/kg, halothane/nitrous oxide/oxygen anesthesia).  At 0.1 mg/kg during opioid anesthesia, cisatracurium had a faster onset and shorter duration of action in children than in adults (Table 1).  Recovery following reversal is faster in children than in adults. </p>
<br><p>At 0.15 mg/kg during opioid anesthesia, cisatracurium had a faster onset and longer clinically effective duration of action in infants aged 1 to 23 months compared to children aged 2 to 12 years (Table 1). </p>
<br><p>Studies were conducted during both opioid-based and halothane-based anesthesia in children aged 1 to 11 months, 1 to 4 years, and 5 to 12 years. Cisatracurium had a faster onset and longer duration of action in infants 1 to 11 months compared to children 1 to 4 years, who in turn have a faster onset and longer duration of action for cisatracurium compared to children 5 to 12 years. </p>
<br><p>The mean time to onset of maximum T<span class="Sub">1 </span> suppression was generally faster for pediatric patients induced with halothane compared to thiopentone/fentanyl and the clinically effective duration (time to 25% recovery) was longer (by up to 15%) for pediatric patients under halothane anesthesia. </p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="be2027f6-e1e2-42f9-b1a6-5309f6b59f6a"></a><a name="section-3.2"></a><p></p>
<h2>Hemodynamics Profile</h2>
<p class="First">The cardiovascular profile of cisatracurium allows it to be administered by rapid bolus at higher multiples of the ED<span class="Sub">95</span> than atracurium.  Cisatracurium has no dose-related effects on mean arterial blood pressure (MAP) or heart rate (HR) following doses ranging from 2 to 8 x ED<span class="Sub">95</span> (&gt; 0.1 to &gt; 0.4 mg/kg), administered over 5 to 10 seconds, in healthy adult patients (Figure 1) or in patients with serious cardiovascular disease (Figure 2).</p>
<p>A total of 141 patients undergoing coronary artery bypass grafting (CABG) have been administered cisatracurium in three active controlled clinical trials and have received doses ranging from 2 to 8 x ED<span class="Sub">95</span>.  While the hemodynamic profile was comparable in both the cisatracurium and active control groups, data for doses above 0.3 mg/kg in this population are limited.</p>
<p>Unlike atracurium, cisatracurium, at therapeutic doses of 2 x ED<span class="Sub">95</span> to 8 x ED<span class="Sub">95</span> (0.1 to 0.4 mg/kg), administered over 5 to 10 seconds, does not cause dose-related elevations in mean plasma histamine concentration.</p>
<p><span class="Bold">Figure 1. Maximum Percent Change from Preinjection in Heart Rate (HR) and Mean Arterial Pressure (MAP) During First 5 Minutes after Initial 4 x ED</span><span class="Bold"><span class="Sub">95 </span></span><span class="Bold">to 8 x ED</span><span class="Bold"><span class="Sub">95</span></span><span class="Bold"> Doses of Cisatracurium in Healthy Adult Patients Receiving Opioid/Nitrous Oxide/Oxygen Anesthesia (n = 44)<br></span></p>
<div class="Figure"><img alt="figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig1.jpg"></div>
<br><p><span class="Bold">Figure 2. Percent Change from </span><span class="Bold">Preinjection in Heart Rate (HR) and Mean Arterial Pressure (MAP) 10 Minutes After an Initial 4</span><span class="Bold"> x ED</span><span class="Bold"><span class="Sub">95 </span></span><span class="Bold">to 8 x ED</span><span class="Bold"><span class="Sub">95</span></span><span class="Bold"> Dose of Cisatracurium in Patients Undergoing CABG Surgery Receiving Oxygen/Fentanyl/Midazolam/Anesthesia (n = 54)</span></p>
<br><div class="Figure"><img alt="figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig2.jpg"></div>
<br><p>No clinically significant changes in MAP or HR were observed following administration of doses up to 0.1 mg/kg cisatracurium over 5 to 10 seconds in 2- to 12-year-old children receiving either halothane/nitrous oxide/oxygen or opioid/nitrous oxide/oxygen anesthesia.  Doses of 0.15 mg/kg cisatracurium administered over 5 seconds were not consistently associated with changes in HR and MAP in pediatric patients aged 1 month to 12 years receiving opioid/nitrous oxide/oxygen or halothane/nitrous oxide/oxygen anesthesia.</p>
<p><span class="Bold">Figure 3. Heart Rate and MAP Change at 1 Minute After the Initial Dose, By Age Group Treatment <br></span></p>
<p><span class="Bold">Group: Cisatracurium 0:3 x ED<span class="Sub">95 </span>Opioid Intubation at 120 Sec.</span></p>
<p>1 to 11 Months</p>
<p> <img alt="figure 3a" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig3.jpg"></p>
<br><p>1 to 5 Years</p>
<p> <img alt="figure 3b" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig4.jpg"></p>
<br><p>5 to 13 Years</p>
<p> <img alt="figure 3c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig5.jpg"></p>
<p>  </p>
<p><span class="Bold">Figure 4. Heart Rate and MAP Change at 1 Minute After the Initial Dose, By Age Group Treatment Group: Cisatracurium H:3 x ED</span><span class="Bold"><span class="Sub">95</span></span><span class="Bold"> Halothane Intubation at 120 Sec. </span></p>
<br><p>1 to 11 Months</p>
<p><img alt="figure 4a" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig6.jpg"> </p>
<p>   </p>
<p>1 to 5 Years</p>
<p> <img alt="figure 4b" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig7.jpg"></p>
<br><br><p>5 to 13 Years</p>
<p> <img alt="figure 4c" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=cis-fig8.jpg"></p>
<br><br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="c7385d32-1477-483b-8499-3b15589c1304"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><span class="Bold">General </span></p>
<br><p>The neuromuscular blocking activity of cisatracurium is due to parent drug.  Cisatracurium plasma concentration-time data following IV bolus administration are best described by a two-compartment open model (with elimination from both compartments) with an elimination half-life (t<span class="Sub">1/2</span>β) of 22 minutes, a plasma clearance (CL) of 4.57 mL/min/kg, and a volume of distribution at steady state (V<span class="Sub">ss</span>) of 145 mL/kg.  Cisatracurium undergoes organ-independent Hofmann elimination (a chemical process dependent on pH and temperature) to form the monoquaternary acrylate metabolite and laudanosine, neither of which has any neuromuscular blocking activity (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>, </span> <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Metabolism</a></span></span></span>).  Following administration of radiolabeled cisatracurium, 95% of the dose was recovered in the urine; less than 10% of the dose was excreted as unchanged parent drug.  Laudanosine, a metabolite of cisatracurium (and atracurium) has been noted to cause transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and, in higher doses, cerebral excitatory effects when administered to several animal species.  The relationship between CNS excitation and laudanosine concentrations in humans has not been established (see <span class="Italics"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span><span class="Bold">, <span class="Italics"><span class="Bold"><a href="#a81ab4a1-b219-4bc3-a1a3-e28b655ec323">Long-Term Use in the Intensive Care Unit [ICU]</a></span></span></span>).  Because cisatracurium is three times more potent than atracurium and lower doses are required, the corresponding laudanosine concentrations following cisatracurium are one third of those that would be expected following an equipotent dose of atracurium (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>,</span>  <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Special Populations</a></span></span>,</span>  <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Intensive Care Unit Patients</a></span></span>).</p>
<br><p>Results from population pharmacokinetic/pharmacodynamic (PK/PD) analyses from 241 healthy surgical patients are summarized in Table 5.</p>
<br><br><p><span class="Bold">Table 5. Key Population PK/PD Parameter Estimates for Cisatracurium in Healthy Surgical Patients* Following 0.1 (2 x ED<span class="Sub">95</span>) to 0.4 mg/kg (8 x ED<span class="Sub">95</span>) Cisatracurium</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top"> <br><span class="Bold">Parameter</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Estimate</span><span class="Bold"><span class="Sup">†</span></span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Magnitude of Interpatient Variability (CV)</span><span class="Bold"><span class="Sup">‡</span></span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">CL (mL/min/kg) <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.57 <br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>16% <br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">V<span class="Sub">ss</span> (mL/kg)<span class="Sup">§</span> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>145 <br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>27% <br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">k<span class="Sub">eo</span> (min-1)<span class="Sup">ll</span> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>0.0575 <br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>61% <br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">EC<span class="Sub">50</span> (ng/mL)<span class="Sup">¶</span> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>141 <br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>52% <br> <br><br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">*</span>Healthy male non-obese patients 19 to 64 years of age with creatinine clearance values greater than 70 mL/min who received cisatracurium during opioid anesthesia and had venous samples collected.</p>
<br><p><span class="Sup">†</span> The percent standard error of the mean (%SEM) ranged from 3% to 12% indicating good precision for the PK/PD estimates. </p>
<br><p><span class="Sup">‡</span> Expressed as a coefficient of variation; the %SEM ranged from 20% to 35% indicating adequate precision for the estimates of interpatient variability. </p>
<br><p><span class="Sup">§</span> V<span class="Sub">ss</span> is the volume of distribution at steady state estimated using a two-compartment model with elimination from both compartments.  V<span class="Sub">ss</span> is equal to the sum of the volume in the central compartment (V<span class="Sub">c</span>) and the volume in the peripheral compartment (Vp); interpatient variability could only be estimated for V<span class="Sub">c</span>.</p>
<br><p> <span class="Sup">ll</span> Rate constant describing the equilibration between plasma concentrations and neuromuscular block. </p>
<br><p><span class="Sup">¶ </span>Concentration required to produce 50% T<span class="Sub">1</span> suppression; an index of patient sensitivity.</p>
<br><p>The magnitude of interpatient variability in CL was low (16%), as expected based on the importance of Hofmann elimination (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>, </span><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Elimination</a></span></span></span></span>).  The magnitudes of interpatient variability in CL and volume of distribution were low in comparison to those for k<span class="Sub">eo</span> and EC<span class="Sub">50</span>.  This suggests that any alterations in the time course of cisatracurium-induced block are more likely to be due to variability in the pharmacodynamic parameters than in the pharmacokinetic parameters.  Parameter estimates from the population pharmacokinetic analyses were supported by noncompartmental pharmacokinetic analyses on data from healthy patients and from special patient populations.</p>
<br><p>Conventional pharmacokinetic analyses have shown that the pharmacokinetics of cisatracurium are proportional to dose between 0.1 (2 x ED<span class="Sub">95</span>) and 0.2 (4 x ED<span class="Sub">95</span>) mg/kg cisatracurium.  In addition, population pharmacokinetic analyses revealed no statistically significant effect of initial dose on CL for doses between 0.1 (2 x ED<span class="Sub">95</span>) and 0.4 (8 x ED<span class="Sub">95</span>) mg/kg cisatracurium.</p>
<br><p><span class="Bold"><br>Distribution</span></p>
<br><p>The volume of distribution of cisatracurium is limited by its large molecular weight and high polarity.  The V<span class="Sub">ss</span> was equal to 145 mL/kg (Table 4) in healthy 19- to 64-year-old surgical patients receiving opioid anesthesia.  The V<span class="Sub">ss</span> was 21% larger in similar patients receiving inhalation anesthesia (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>,</span>  <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Special Populations</a></span></span><span class="Italics">,</span>  </span><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Other Patient Factors</a></span></span>). </p>
<br><br><br><p><span class="Bold">Protein Binding</span></p>
<br><p>The binding of cisatracurium to plasma proteins has not been successfully studied due to its rapid degradation at physiologic pH.  Inhibition of degradation requires nonphysiological conditions of temperature and pH which are associated with changes in protein binding.</p>
<br><br><br><p><span class="Bold">Metabolism</span></p>
<br><p>The degradation of cisatracurium is largely independent of liver metabolism.  Results from <span class="Italics"><span class="Italics">in vitro</span></span> experiments suggest that cisatracurium undergoes Hofmann elimination (a pH and temperature-dependent chemical process) to form laudanosine (see <span class="Bold"><span class="Italics"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span></span><span class="Bold">,</span>  <span class="Bold"><span class="Italics"><span class="Bold"><a href="#a81ab4a1-b219-4bc3-a1a3-e28b655ec323">Long-Term Use in the Intensive Care Unit [ICU]</a></span></span></span>) and the monoquaternary acrylate metabolite.  The monoquaternary acrylate undergoes hydrolysis by non-specific plasma esterases to form the monoquaternary alcohol (MQA) metabolite.  The MQA metabolite can also undergo Hofmann elimination but at a much slower rate than cisatracurium.  Laudanosine is further metabolized to desmethyl metabolites which are conjugated with glucuronic acid and excreted in the urine.</p>
<br><p>Organ-independent Hofmann elimination is the predominant pathway for the elimination of cisatracurium.  The liver and kidney play a minor role in the elimination of cisatracurium but are primary pathways for the elimination of metabolites.  Therefore, the t<span class="Sub">1/2</span>ß values of metabolites (including laudanosine) are longer in patients with kidney or liver dysfunction and metabolite concentrations may be higher after long-term administration (see <span class="Bold"><span class="Italics"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span><span class="Italics">,</span></span>  <span class="Italics"><span class="Italics"><span class="Bold"><span class="Italics"><span class="Bold"><a href="#a81ab4a1-b219-4bc3-a1a3-e28b655ec323">Long-Term Use in the Intensive Care Unit [ICU]</a></span></span></span></span></span>).  Most importantly, C<span class="Sub">max</span> values of laudanosine are significantly lower in healthy surgical patients receiving infusions of cisatracurium than in patients receiving infusions of atracurium (mean ± SD C<span class="Sub">max</span>: 60 ± 52 and 342 ± 93 ng/mL, respectively).</p>
<br><br><br><p><span class="Bold">Elimination</span></p>
<br><p><span class="Underline">Clearance and Half-life</span></p>
<br><p>Mean CL values for cisatracurium ranged from 4.5 to 5.7 mL/min/kg in studies of healthy surgical patients.  Compartmental pharmacokinetic modeling suggests that approximately 80% of the CL is accounted for by Hofmann elimination and the remaining 20% by renal and hepatic elimination.  These findings are consistent with the low magnitude of interpatient variability in CL (16%) estimated as part of the population PK/PD analyses and with the recovery of parent and metabolites in urine.  Following <span class="Sup">14</span>C-cisatracurium administration to 6 healthy male patients, 95% of the dose was recovered in the urine (mostly as conjugated metabolites) and 4% in the feces; less than 10% of the dose was excreted as unchanged parent drug in the urine.  In 12 healthy surgical patients receiving non-radiolabeled cisatracurium who had Foley catheters placed for surgical management, approximately 15% of the dose was excreted unchanged in the urine.</p>
<br><p>In studies of healthy surgical patients, mean t<span class="Sub">1/2</span>β values of cisatracurium ranged from 22 to 29 minutes and were consistent with the t<span class="Sub">1/2</span>β of cisatracurium <span class="Italics"><span class="Italics">in vitro </span></span>(29 minutes).  The mean ± SD t<span class="Sub">1/2</span>β values of laudanosine were 3.1 ± 0.4 and 3.3 ± 2.1 hours in healthy surgical patients receiving cisatracurium (n = 10) or atracurium (n = 10), respectively.  During IV infusions of cisatracurium, peak plasma concentrations (C<span class="Sub">max</span>) of laudanosine and the MQA metabolite are approximately 6% and 11% of the parent compound, respectively. </p>
<br><br><p><span class="Bold">Special Populations</span></p>
<p><span class="Underline">Geriatric Patients (≥ 65 years)</span></p>
<br><p>The results of conventional pharmacokinetic analysis from a study of 12 healthy elderly patients and 12 healthy young adult patients receiving a single IV dose of 0.1 mg/kg cisatracurium are summarized in Table 6.  Plasma clearances of cisatracurium were not affected by age; however, the volumes of distribution were slightly larger in elderly patients than in young patients resulting in slightly longer t<span class="Sub">1/2</span>β values for cisatracurium. The rate of equilibration between plasma cisatracurium concentrations and neuromuscular block was slower in elderly patients than in young patients (mean ± SD k<span class="Sub">eo</span>: 0.071 ± 0.036 and 0.105 ± 0.021 minutes<span class="Sup">-1</span>, respectively); there was no difference in the patient sensitivity to cisatracurium-induced block, as indicated by EC<span class="Sub">50</span> values (mean ± SD EC<span class="Sub">50</span>: 91 ± 22 and 89 ± 23 ng/mL, respectively).  These changes were consistent with the 1-minute slower times to maximum block in elderly patients receiving 0.1 mg/kg cisatracurium, when compared to young patients receiving the same dose.  The minor differences in PK/PD parameters of cisatracurium between elderly patients and young patients were not associated with clinically significant differences in the recovery profile of cisatracurium.</p>
<br><br><br><p><span class="Bold">Table 6. Pharmacokinetic Parameters* of Cisatracurium in Healthy Elderly and Young Adult Patients Following 0.1 mg/kg (2 x ED</span><span class="Bold"><span class="Sub">95</span></span><span class="Bold">) Cisatracurium (Isoflurane/Nitrous Oxide/Oxygen Anesthesia)</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Parameter</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Healthy Elderly </span><br> <br><span class="Bold">Patients</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Healthy Young </span><br> <br><span class="Bold">Adult Patients</span><br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Elimination Half-Life (t<span class="Sub">½</span>β, min) <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>25.8 ± 3.6<span class="Sup">†</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>22.1 ± 2.5<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Volume of Distribution at<br>Steady State<span class="Sup">‡</span> (mL/kg)<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>156 ± 17<span class="Sup">†</span> <br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>133 ± 15 <br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Plasma Clearance (mL/min/kg)<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>5.7 ± 1<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>5.3 ± 0.9<br> <br><br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">*</span> Values presented are mean ± SD. </p>
<br><p><span class="Sup">†</span>P &lt; 0.05 for comparisons between healthy elderly and healthy young adult patients.</p>
<br><p><span class="Sup">‡</span> Volume of distribution is underestimated because elimination from the peripheral compartment is ignored.</p>
<br><p><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></span></p>
<br><p>Table 7 summarizes the conventional pharmacokinetic analysis from a study of cisatracurium in 13 patients with end-stage liver disease undergoing liver transplantation and 11 healthy adult patients undergoing elective surgery.  The slightly larger volumes of distribution in liver transplant patients were associated with slightly higher plasma clearances of cisatracurium.  The parallel changes in these parameters resulted in no difference in t<span class="Sub">½</span>β values.  There were no differences in k<span class="Sub">eo</span> or EC<span class="Sub">50</span> between patient groups.  The times to maximum block were approximately one minute faster in liver transplant patients than in healthy adult patients receiving 0.1 mg/kg cisatracurium.  These minor differences in pharmacokinetics were not associated with clinically significant differences in the recovery profile of cisatracurium.</p>
<br><p>The t<span class="Sub">½</span>β values of metabolites are longer in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> and concentrations may be higher after long-term administration (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>,</span>  <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Special Populations</a></span></span><span class="Italics">,</span>  </span><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Intensive Care Unit Patients</a></span></span>). </p>
<br><p><span class="Bold">Table 7. Pharmacokinetic Parameters* of Cisatracurium in Healthy Adult Patients and in Patients Undergoing Liver Transplantation Following 0.1 mg/kg (2 x ED</span><span class="Bold"><span class="Sub">95</span></span><span class="Bold">) Cisatracurium (Isoflurane/Nitrous Oxide/Oxygen Anesthesia)</span>   </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Parameter</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Liver Transplant Patients</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Healthy Adult Patients</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Elimination Half-Life (t<span class="Sub">½</span>β, min)<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>24.4 ± 2.9 <br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>23.5 ± 3.5<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Volume of Distribution at<br>Steady State<span class="Sup">‡</span> (mL/kg)<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>195 ± 38<span class="Sup">† </span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>161 ± 23<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Plasma Clearance (mL/min/kg) <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>6.6 ± 1.1<span class="Sup">†</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>5.7 ± 0.8<br> <br><br>
</td>
</tr>
</tbody></table>
<p>* Values presented are mean ± SD.</p>
<br><p><span class="Sup">†</span>P &lt; 0.05 for comparisons between liver transplant patients and healthy adult patients. </p>
<br><p><span class="Sup"> ‡</span>Volume of distribution is underestimated because elimination from the peripheral compartment is ignored.</p>
<br><p><span class="Underline">Patients with Renal Dysfunction</span></p>
<br><p>Results from a conventional pharmacokinetic study of cisatracurium in 13 healthy adult patients and 15 patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) undergoing elective surgery are summarized in Table 8.  The PK/PD parameters of cisatracurium were similar in healthy adult patients and ESRD patients.  The times to 90% block were approximately one minute slower in ESRD patients following 0.1 mg/kg cisatracurium. There were no differences in the durations or rates of recovery of cisatracurium between ESRD and healthy adult patients. </p>
<br><p>The t<span class="Sub">½</span>β values of metabolites are longer in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and concentrations may be higher after long-term administration (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>,</span>  <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Special Populations</a></span></span>,  </span><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Intensive Care Unit Patients</a></span></span>).</p>
<br><p><span class="Bold">Table 8. Pharmacokinetic Parameters* for Cisatracurium in Healthy Adult Patients and in Patients With End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> (ESRD) Receiving 0.1 mg/kg (2 x ED</span><span class="Bold"><span class="Sub">95</span></span><span class="Bold">) Cisatracurium (Opioid/Nitrous Oxide/Oxygen Anesthesia)</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Parameter</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Healthy Adult Patients</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">ESRD Patients</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Elimination Half-Life (t<span class="Sub">½</span>β, min) <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>29.4 ± 4.1<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>32.3 ± 6.3<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Volume of Distribution at <br>Steady State<span class="Sup">†</span> (mL/kg)<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>149 ± 35<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>160 ± 32<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Plasma Clearance (mL/min/kg) <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.66 ± 0.86<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.26 ± 0.62<br> <br><br>
</td>
</tr>
</tbody></table>
<p>* Values presented are mean ± SD. </p>
<br><p><span class="Sup">† </span>Volume of distribution is underestimated because elimination from the peripheral compartment is ignored.</p>
<br><p>Population pharmacokinetic analyses revealed that patients with creatinine clearances  ≤ 70 mL/min had a slower rate of equilibration between plasma concentrations and neuromuscular block than patients with normal renal function; this change was associated with a slightly slower (~ 40 seconds) predicted time to 90% T<span class="Sub">1</span> suppression in patients with renal dysfunction following 0.1 mg/kg cisatracurium.  There was no clinically significant alteration in the recovery profile of cisatracurium in patients with renal dysfunction.  The recovery profile of cisatracurium is unchanged in the presence of renal or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, which is consistent with predominantly organ-independent elimination. </p>
<br><br><br><p><span class="Underline">Intensive Care Unit (ICU) Patients</span></p>
<p>The pharmacokinetics of cisatracurium, atracurium, and their metabolites were determined in six ICU patients receiving cisatracurium and in six ICU patients receiving atracurium and are presented in Table 9.  The plasma clearances of cisatracurium and atracurium are similar.  The volume of distribution was larger and the t<span class="Sub">1/2</span>β was longer for cisatracurium than for atracurium.  The relationships between plasma cisatracurium or atracurium concentrations and neuromuscular block have not been evaluated in ICU patients.  The minor differences in pharmacokinetics were not associated with any differences in the recovery profiles of cisatracurium and atracurium in ICU patients. </p>
<br><br><br><p><span class="Bold">Table 9. Parameter Estimates* for Cisatracurium, Atracurium, and Metabolites in ICU Patients After Long-Term (24 to 48 Hour) Administration of Cisatracurium or Atracurium Besylate <br></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="right" colspan="2" valign="top"> <br> <br> <br><br><span class="Bold">Parameter</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Cisatracurium  (n = 6)</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Atracurium  (n = 6)</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Parent Compound<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>CL (mL/min/kg)<br> <br>t<span class="Sub">½</span>β (min)<br><br>Vβ (mL/kg)<span class="Sup">‡</span><br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>7.45 ± 1.02<br> <br>26.8 ± 11.1<br><br>280 ± 103<br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>7.49 ± 0.66<span class="Sup">†</span><br> <br>16.5 ± 6<span class="Sup">†</span><br><br>178 ± 71<span class="Sup">†</span><br><br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Laudanosine <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>C<span class="Sub">max</span> (ng/mL) <br> <br>t<span class="Sub">½</span>β (hrs)<br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>707 ± 360 <br> <br>6.6 ± 4.1<br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2318 ± 1498 <br> <br>8.4 ± 7.3<br><br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">MQA metabolite <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>C<span class="Sub">max</span> (ng/mL) <br> <br>t<span class="Sub">½</span>β (min) <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>152 to 181<span class="Sup">§ </span><br> <br>26 to 31<span class="Sup">§</span> <br><br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>943 ± 333<span class="Sup">ll</span> <br> <br>21 to 58<span class="Sup">§</span> <br><br><br>
</td>
</tr>
</tbody></table>
<p>* Presented as mean ± standard deviation.</p>
<br><p><span class="Sup">†</span> n = 5. </p>
<br><p><span class="Sup">‡ </span>Volume of distribution during the terminal elimination phase, an underestimate because elimination from the peripheral compartment is ignored. </p>
<br><p><span class="Sup">§</span> n = 2, range presented. </p>
<br><p><span class="Sup">ll</span> n = 3.</p>
<br><p>Plasma metabolite pharmacokinetics are listed in Table 9.  Limited pharmacokinetic data are available for patients with liver/<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span> receiving cisatracurium.  Data from studies of atracurium demonstrate that renal/<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in ICU patients produces little to no effect on its pharmacokinetics, but decreases the biotransformation and elimination of the metabolites.  Following atracurium, t<span class="Sub">1/2</span>β values for laudanosine were longer in ICU patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> than in ICU patients with normal renal function (15 and 6 hours, respectively).  The t<span class="Sub">1/2</span>β values of laudanosine were 39 ± 14 hours in ICU patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> receiving atracurium after an unsuccessful liver transplantation and 5 ± 2 hours in similar ICU patients after successful liver transplantation. Therefore, relative to ICU patients with normal renal and hepatic function receiving cisatracurium, metabolite concentrations (plasma and tissues) may be higher in ICU patients with renal or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (see<span class="Bold"><span class="Italics"> </span><span class="Italics"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span>,<span class="Italics">  </span></span><span class="Bold"><span class="Italics"><span class="Bold"><a href="#a81ab4a1-b219-4bc3-a1a3-e28b655ec323">Long-Term Use in the Intensive Care Unit [ICU]</a></span></span></span>).  Consistent with the decreased infusion rate requirements for cisatracurium, metabolite concentrations were lower in patients receiving cisatracurium than in patients receiving atracurium besylate.</p>
<br><p><span class="Underline">Pediatric Patients</span></p>
<br><p>The population PK/PD of cisatracurium were described in 20 healthy pediatric patients during halothane anesthesia, using the same model developed for healthy adult patients. The CL was higher in healthy pediatric patients (5.89 mL/min/kg) than in healthy adult patients (4.57 mL/min/kg) during opioid anesthesia.  The rate of equilibration between plasma concentrations and neuromuscular block, as indicated by k<span class="Sub">eo</span>, was faster in healthy pediatric patients receiving halothane anesthesia (0.133 minutes<span class="Sup">-1</span>) than in healthy adult patients receiving opioid anesthesia (0.0575 minutes<span class="Sup">-1</span>). The EC<span class="Sub">50</span> in healthy pediatric patients (125 ng/mL) was similar to the value in healthy adult patients (141 ng/mL) during opioid anesthesia.  The minor differences in the PK/PD parameters of cisatracurium were associated with a faster time to onset and a shorter duration of cisatracurium-induced neuromuscular block in pediatric patients.</p>
<br><p><span class="Underline">Other Patient Factors</span></p>
<br><p>Population PK/PD analyses revealed that gender and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> were associated with statistically significant effects on the pharmacokinetics and/or pharmacodynamics of cisatracurium; these factors were not associated with clinically significant alterations in the predicted onset or recovery profile of cisatracurium.  The use of inhalation agents was associated with a 21% larger V<span class="Sub">ss</span> , a 78% larger k<span class="Sub">eo</span>, and a 15% lower EC<span class="Sub">50</span> for cisatracurium.  These changes resulted in a slightly faster (~ 45 seconds) predicted time to 90% T<span class="Sub">1</span> suppression in patients receiving 0.1 mg/kg cisatracurium during inhalation anesthesia than in patients receiving the same dose of cisatracurium during opioid anesthesia; however, there were no clinically significant differences in the predicted recovery profile of cisatracurium between patient groups.</p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e8946647-8fa3-4a0b-96f9-7a2da2a5ff8b"></a><a name="section-3.4"></a><p></p>
<h2>Individualization of Dosages</h2>
<p class="First">DOSES OF <span class="Bold">CISATRACURIUM</span> SHOULD BE INDIVIDUALIZED AND A PERIPHERAL NERVE STIMULATOR SHOULD BE USED TO MEASURE NEUROMUSCULAR FUNCTION DURING ADMINISTRATION OF <span class="Bold">CISATRACURIUM</span> IN ORDER TO MONITOR DRUG EFFECT, TO DETERMINE THE NEED FOR ADDITIONAL DOSES, AND TO CONFIRM RECOVERY FROM NEUROMUSCULAR BLOCK.</p>
<p>Based on the known action of cisatracurium and other neuromuscular blocking agents, the following factors should be considered when administering cisatracurium.</p>
<br><p><span class="Bold">Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></span></p>
<br><p>See<span class="Italics"><span class="Bold"> </span></span><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span><span class="Bold">.</span></p>
<br><p><span class="Bold">Long-Term Use in the Intensive Care Unit (ICU)</span></p>
<p>The long-term infusion (up to 6 days) of cisatracurium during mechanical ventilation in the ICU has been evaluated in two studies.  Average infusion rates of approximately 3 mcg/kg/min (range: 0.5 to 10.2) were required to achieve adequate neuromuscular block.  As with other neuromuscular blocking agents, these data indicate the presence of wide interpatient variability in dosage requirements.  In addition, dosage requirements may increase or decrease with time (see <span class="Bold"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span>).  Use of cisatracurium in the ICU for longer than 6 days has not been studied.</p>
<br><p><span class="Bold">Drugs or Conditions Causing Potentiation of or Resistance to Neuromuscular Block</span></p>
<p>Persons with certain pre-existing conditions or receiving certain drugs may require individualization of dosing (see <span class="Bold"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span>).</p>
<br><p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span><span class="Italics"></span></span></p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> have been shown to develop resistance to nondepolarizing neuromuscular blocking agents, and may require individualization of dosing (see <span class="Bold"><span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="feb249e6-b8cf-4665-94de-e7ca4367043b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Cisatracurium Besylate Injection is an intermediate-onset/intermediate-duration neuromuscular blocking agent indicated for inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> during surgery or mechanical ventilation in the ICU.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="bd3b8677-dfd3-4e80-9d3a-1369511cc5f1"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Cisatracurium is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product and its components.  The 10 mL multiple dose vials of cisatracurium is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see <span class="Bold"><a href="#a48a9215-2f2b-4f8b-bf5d-863e08606306">WARNINGS</a></span> and<span class="Bold"><span class="Italics"> </span><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a>,</span> <span class="Bold"><span class="Italics"><a href="#f28d2edc-681b-4f6a-8cf3-9c67db2f89a4">Pediatric Use</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a48a9215-2f2b-4f8b-bf5d-863e08606306"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<div class="Section" data-sectionCode="34071-1">
<a name="d4a6bd03-cff4-4c9c-97a3-40c55de8dafd"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to neuromuscular blocking agents, including cisatracurium, have been reported.  These reactions have in some cases been life-threatening and fatal.  Due to the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken.  Precautions should also be taken in those individuals who have had previous <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="bc2374fc-52e5-4fce-be37-e5afc77cf15b"></a><a name="section-6.2"></a><p></p>
<h2>Administration</h2>
<p class="First"><span class="Bold">CISATRACURIUM</span> SHOULD BE ADMINISTERED IN CAREFULLY ADJUSTED DOSAGE BY OR UNDER THE SUPERVISION OF EXPERIENCED CLINICIANS WHO ARE FAMILIAR WITH THE DRUG'S ACTIONS AND THE POSSIBLE COMPLICATIONS OF ITS USE.  THE DRUG SHOULD NOT BE ADMINISTERED UNLESS PERSONNEL AND FACILITIES FOR RESUSCITATION AND LIFE SUPPORT (TRACHEAL INTUBATION, ARTIFICIAL VENTILATION, OXYGEN THERAPY), AND AN ANTAGONIST OF <span class="Bold">CISATRACURIUM</span> ARE IMMEDIATELY AVAILABLE.  IT IS RECOMMENDED THAT A PERIPHERAL NERVE STIMULATOR BE USED TO MEASURE NEUROMUSCULAR FUNCTION DURING THE ADMINISTRATION OF <span class="Bold">CISATRACURIUM</span> IN ORDER TO MONITOR DRUG EFFECT, DETERMINE THE NEED FOR ADDITIONAL DOSES, AND CONFIRM RECOVERY FROM NEUROMUSCULAR BLOCK.</p>
<p><span class="Bold">CISATRACURIUM</span> HAS NO KNOWN EFFECT ON CONSCIOUSNESS, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">PAIN</span> THRESHOLD, OR CEREBRATION.  TO AVOID DISTRESS TO THE PATIENT, NEUROMUSCULAR BLOCK SHOULD NOT BE INDUCED BEFORE <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">UNCONSCIOUSNESS</span>.</p>
<p>Cisatracurium Besylate Injection is acidic (pH 3.25 to 3.65) and may not be compatible with alkaline solutions having a pH greater than 8.5 (e.g., barbiturate solutions).</p>
<p>The 10 mL multiple dose vials of cisatracurium contain benzyl alcohol, which is potentially toxic when administered locally to neural tissue.  Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>), particularly in neonates, and an increased incidence of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>, particularly in small preterm infants.  There have been rare reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol.  The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol.  Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered.  The amount of benzyl alcohol at which toxicity may occur is not known.  If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources.  Single use vials (5 mL and 20 mL) of cisatracurium do not contain benzyl alcohol (see <span class="Bold"><a href="#a48a9215-2f2b-4f8b-bf5d-863e08606306">WARNINGS</a></span> and <span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a>,</span> <span class="Bold"><span class="Italics"><span class="Italics"><a href="#f28d2edc-681b-4f6a-8cf3-9c67db2f89a4">Pediatric Use</a></span></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bfe12ce5-08e7-4d80-b276-03138f9637e3"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">Because of its intermediate onset of action, cisatracurium is not recommended for rapid sequence endotracheal intubation. </p>
<p>Recommended doses of cisatracurium have no clinically significant effects on heart rate; therefore, cisatracurium will not counteract the <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> produced by many anesthetic agents or by vagal stimulation. </p>
<p>Neuromuscular blocking agents may have a profound effect in patients with neuromuscular diseases (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and the <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span>).  In these and other conditions in which prolonged neuromuscular block is a possibility (e.g., <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">carcinomatosis</span>), the use of a peripheral nerve stimulator and a dose of not more than 0.02 mg/kg cisatracurium is recommended to assess the level of neuromuscular block and to monitor dosage requirements.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> have been shown to develop resistance to non-depolarizing neuromuscular blocking agents, including atracurium.  The extent of altered response depends upon the size of the burn and the time elapsed since the burn injury.  Cisatracurium has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>; however, based on its structural similarity to atracurium, the possibility of increased dosing requirements and shortened duration of action must be considered if cisatracurium is administered to burn patients.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span> or <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span> also may demonstrate resistance to non-depolarizing muscle relaxants in the affected limbs.  To avoid inaccurate dosing, neuromuscular monitoring should be performed on a non-paretic limb. </p>
<p>Acid-base and/or serum electrolyte abnormalities may potentiate or antagonize the action of neuromuscular blocking agents.  No data are available to support the use of cisatracurium by intramuscular injection.</p>
<div class="Section" data-sectionCode="42232-9">
<a name="ef07d161-2bf5-426b-9a4e-a67c2c113b91"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Since allergic cross-reactivity has been reported in this class, request information from your patients about previous <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to other neuromuscular blocking agents.  In addition, inform your patients that severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to neuromuscular blocking agents, including cisatracurium have been reported (see <span class="Bold"><a href="#bd3b8677-dfd3-4e80-9d3a-1369511cc5f1">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="db3f2df8-a6a8-4b99-b614-e66b7a1bd451"></a><a name="section-7.2"></a><p></p>
<h2>Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h2>
<p class="First">No clinically significant alterations in the recovery profile were observed in patients with renal dysfunction or in patients with end-stage liver disease following a 0.1 mg/kg dose of cisatracurium.  The onset time was approximately 1 minute faster in patients with end-stage liver disease and approximately 1 minute slower in patients with renal dysfunction than in healthy adult control patients.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a6b1e22c-b4d2-4dfc-9034-713acaedbf0c"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span> (MH)</h2>
<p class="First">In a study of MH-susceptible pigs, cisatracurium besylate (highest dose 2000 mcg/kg equivalent to 3 x ED<span class="Sub">95</span> in pigs and 40 x ED<span class="Sub">95</span> in humans) did not trigger MH.  Cisatracurium besylate has not been studied in MH-susceptible patients.  Because MH can develop in the absence of established triggering agents, the clinician should be prepared to recognize and treat MH in any patient undergoing general anesthesia.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a81ab4a1-b219-4bc3-a1a3-e28b655ec323"></a><a name="section-7.4"></a><p></p>
<h2>Long-Term Use in the Intensive Care Unit (ICU)</h2>
<p class="First">Long-term infusion (up to 6 days) of cisatracurium during mechanical ventilation in the ICU has been safely used in two studies.  Dosage requirements may increase or decrease with time  (see<span class="Bold"></span><span class="Bold"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">CLINICAL PHARMACOLOGY</a></span><span class="Italics"><span class="Bold">, </span></span><span class="Italics"><span class="Bold"><a href="#e8946647-8fa3-4a0b-96f9-7a2da2a5ff8b">Individualization of Dosages</a></span></span><span class="Bold">).</span>  </p>
<p>Little information is available on the plasma levels and clinical consequences of cisatracurium metabolites that may accumulate during days to weeks of cisatracurium administration in ICU patients.  Laudanosine, a major, biologically active metabolite of atracurium and cisatracurium without neuromuscular blocking activity, produces transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and, in higher doses, cerebral excitatory effects (generalized <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) when administered to several species of animals.  There have been rare spontaneous reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in ICU patients who have received atracurium or other agents.  These patients usually had predisposing causes (such as cranial <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, <span class="product-label-link" type="condition" conceptid="377845" conceptname="Anoxic encephalopathy">hypoxic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="372547" conceptname="Viral encephalitis">viral encephalitis</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>).  There are insufficient data to determine whether or not laudanosine contributes to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in ICU patients.  Consistent with the decreased infusion rate requirements for cisatracurium, laudanosine concentrations were lower in patients receiving cisatracurium than in patients receiving atracurium for up to 48 hours   (see <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>,</span>  <span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Special Populations</a></span></span><span class="Italics">, </span> </span><span class="Italics"><span class="Bold"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Intensive Care Unit Patients</a></span></span>). <br>In a randomized, double-blind study using train-of-four nerve stimulator monitoring to maintain at least one visible twitch, evaluable patients treated with cisatracurium (n = 19) recovered neuromuscular function (T<span class="Sub">4</span>:T<span class="Sub">1</span> ratio ≥ 70%) following termination of infusion in approximately 55 minutes (range: 20 to 270) whereas evaluable vecuronium-treated patients (n = 12) recovered in 178 minutes (range: 40 minutes to 33 hours).  In another study comparing cisatracurium and atracurium, patients recovered neuromuscular function in approximately 50 minutes for both cisatracurium (range: 20 to 175; n = 34) and atracurium (range: 35 to 85; n = 15).</p>
<br><p>WHENEVER THE USE OF <span class="Bold">CISATRACURIUM</span> OR ANY OTHER NEUROMUSCULAR BLOCKING AGENT IN THE ICU IS CONTEMPLATED, IT IS RECOMMENDED THAT NEUROMUSCULAR FUNCTION BE MONITORED DURING ADMINISTRATION WITH A NERVE STIMULATOR.  ADDITIONAL DOSES OF <span class="Bold">CISATRACURIUM</span> OR ANY OTHER NEUROMUSCULAR BLOCKING AGENT SHOULD NOT BE GIVEN BEFORE THERE IS A DEFINITE RESPONSE TO NERVE STIMULATION.  IF NO RESPONSE IS ELICITED, INFUSION ADMINISTRATION SHOULD BE DISCONTINUED UNTIL A RESPONSE RETURNS.</p>
<br><p>The effects of hemofiltration, hemodialysis, and hemoperfusion on plasma levels of cisatracurium and its metabolites are unknown.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="be38982d-712d-45a6-a465-3c5407e74175"></a><a name="section-7.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Cisatracurium has been used safely following varying degrees of recovery from succinylcholine-induced neuromuscular block.  Administration of 0.1 mg/kg (2 x ED<span class="Sub">95</span>) cisatracurium at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced ≥ 95% neuromuscular block.  The time to onset of maximum block following cisatracurium is approximately 2 minutes faster with prior administration of succinylcholine.  Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of cisatracurium. Infusion requirements of cisatracurium in patients administered succinylcholine prior to infusions of cisatracurium were comparable to or slightly greater than when succinylcholine was not administered.</p>
<p>The use of cisatracurium before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.</p>
<p>Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of cisatracurium.</p>
<p>Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of cisatracurium and decrease the required infusion rate of cisatracurium.  The magnitude of these effects may depend on the duration of administration of the volatile agents.   Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of cisatracurium and therefore, no adjustment to the initial dose should be necessary when cisatracurium is administered shortly after initiation of volatile agents.  In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of cisatracurium may be necessary.  The average infusion rate requirement may be decreased by as much as 30% to 40%.</p>
<p>In clinical studies propofol had no effect on the duration of action or dosing requirements for cisatracurium.</p>
<p>Other drugs which may enhance the neuromuscular blocking action of non-depolarizing agents such as cisatracurium include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.</p>
<p>Resistance to the neuromuscular blocking action of non-depolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.  While the effects of chronic phenytoin or carbamazepine therapy on the action of cisatracurium are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f3501674-a49b-40a9-9106-4e20deb4fb34"></a><a name="section-7.6"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">None known.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bb9dfedf-fe54-4552-b78a-1a16b61a6447"></a><a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenesis and fertility studies have not been performed.  Cisatracurium besylate was evaluated in a battery of four short-term mutagenicity tests. It was non-mutagenic in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> assay, a rat bone marrow cytogenetic assay, and an <span class="Italics"><span class="Italics">in vitro</span></span> human lymphocyte cytogenetics assay.   As was the case with atracurium, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay was positive both in the presence and absence of exogenous metabolic activation (rat liver S-9).  In the absence of S-9, cisatracurium besylate was positive at <span class="Italics"><span class="Italics">in vitro</span></span> cisatracurium concentrations of 40 mcg/mL and higher.  The highest non-mutagenic concentration (30 mcg/mL) and incubation time (4 hours) resulted in an AUC approximately 120 times that noted in clinical studies and approximately 8.5 times the mean peak clinical concentration noted.  In the presence of S-9, cisatracurium besylate was positive at a cisatracurium concentration of 300 mcg/mL but not at lower or higher concentrations.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d97ec695-97fc-4634-b711-d71530757602"></a><a name="section-7.8"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects</span></p>
<p><span class="Underline">Pregnancy Category B</span></p>
<p>Teratology testing in nonventilated pregnant rats treated subcutaneously with maximum subparalyzing doses (4 mg/kg daily; equivalent to 8 x the human ED<span class="Sub">95</span> following a bolus dose of 0.2 mg/kg IV) and in ventilated rats treated intravenously with paralyzing doses of cisatracurium at 0.5 and 1 mg/kg; equivalent to 10 x and 20 x the human ED<span class="Sub">95</span> dose, respectively, revealed no maternal or fetal toxicity or teratogenic effects.  There are no adequate and well-controlled studies of cisatracurium in pregnant women.  Because animal studies are not always predictive of human response, cisatracurium should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a073d992-d1a0-4111-a893-68c64925ca80"></a><a name="section-7.9"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The use of cisatracurium during labor, vaginal delivery, or cesarean section has not been studied in humans and it is not known whether cisatracurium administered to the mother has effects on the fetus.  Doses of 0.2 or 0.4 mg/kg cisatracurium given to female beagles undergoing cesarean section resulted in negligible levels of cisatracurium in umbilical vessel blood of neonates and no deleterious effects on the puppies.  The action of neuromuscular blocking agents may be enhanced by magnesium salts administered for the management of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bb719a8f-a6ba-4e6e-b813-267109d8c825"></a><a name="section-7.10"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether cisatracurium besylate is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised following administration of cisatracurium to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f28d2edc-681b-4f6a-8cf3-9c67db2f89a4"></a><a name="section-7.11"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Cisatracurium has not been studied in pediatric patients below the age of 1 month (see <span class="Bold"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#bac0e4e2-ed66-4d4a-895d-fc2e7ade8e65">DOSAGE AND ADMINISTRATION</a> </span>for clinical experience and recommendations for use in children 1 month to 12 years of age). Intubation of the trachea in patients 1 to 4 years old was facilitated more reliably when cisatracurium was used in combination with halothane than when opioids and nitrous oxide were used for induction of anesthesia. </p>
<p>The 10 mL multiple dose vials of cisatracurium contain benzyl alcohol as a preservative.  Benzyl alcohol, a component of this product, has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, particularly in pediatric patients.  The “gasping syndrome?, (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages &gt;99 mg/kg/day in neonates and low-birth-weight neonates.  Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.  Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome?, the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity.  Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bf28cda5-53e1-455d-986c-7e7b254f45ff"></a><a name="section-7.12"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of cisatracurium, 57 were 65 and over, 63 were 70 and over, and 15 were 80 and over.  The geriatric population included a subset of patients with significant cardiovascular disease (see <span class="Bold"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">CLINICAL</a> </span><span class="Bold"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">PHARMACOLOGY</a></span><span class="Bold"><span class="Italics">, </span><span class="Italics"><a href="#be2027f6-e1e2-42f9-b1a6-5309f6b59f6a">Hemodynamics Profile</a></span> </span> and <span class="Bold"><span class="Italics"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Special Populations ,</a></span> </span><span class="Italics"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Geriatric Patients</a></span>).  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between elderly and younger subjects, but greater sensitivity of some older individuals to cisatracurium cannot be ruled out. </p>
<p>Minor differences in the pharmacokinetics of cisatracurium between elderly and young adult patients are not associated with clinically significant differences in the recovery profile of cisatracurium following a single 0.1 mg/kg dose; the time to maximum block is approximately 1 minute slower in elderly patients (see <span class="Bold"><span class="Italics"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">CLINICAL PHARMACOLOGY</a></span>,</span> <span class="Bold"><span class="Italics"><a href="#c7385d32-1477-483b-8499-3b15589c1304">Pharmacokinetics</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ba45339b-572e-498d-b26f-197e0eded648"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="e561ed28-ae82-4ade-835a-763be41c935d"></a><a name="section-8.1"></a><p></p>
<h2>Observed in Clinical Trials of Surgical Patients</h2>
<p class="First">Adverse experiences were uncommon among the 945 surgical patients who received cisatracurium in conjunction with other drugs in US and European clinical studies in the course of a wide variety of procedures in patients receiving opioid, propofol, or inhalation anesthesia.  The following adverse experiences were judged by investigators during the clinical trials to have a possible causal relationship to administration of cisatracurium:</p>
<br><p><span class="Bold">Incidence Greater than 1% <br></span></p>
<p>None.</p>
<p><span class="Bold">Incidence Less than 1%</span></p>
<p><span class="Underline">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (0.4%)</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (0.2%)</p>
<p><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (0.2%)</p>
<p><span class="Underline">Respiratory</span></p>
<p><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (0.2%)</p>
<p><span class="Underline">Dermatological</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.1%)</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ab9b38b9-ea1c-4ffa-bd61-6375bd55a8b6"></a><a name="section-8.2"></a><p></p>
<h2>Observed in Clinical Trials of Intensive Care Unit Patients</h2>
<p class="First">Adverse experiences were uncommon among the 68 ICU patients who received cisatracurium in conjunction with other drugs in US and European clinical studies.  One patient experienced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  In one of the two ICU studies, a randomized and double-blind study of ICU patients using TOF neuromuscular monitoring, there were two reports of prolonged recovery (167 and 270 minutes) among 28 patients administered cisatracurium and 13 reports of prolonged recovery (range: 90 minutes to 33 hours) among 30 patients administered vecuronium.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="dc570e1e-0104-497a-aee3-792d6cc2959f"></a><a name="section-8.3"></a><p></p>
<h2>Observed During Clinical Practice</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of cisatracurium besylate in conjunction with one or more anesthetic agents in clinical practice.  Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to cisatracurium besylate.</p>
<br><p><span class="Bold">General</span></p>
<p>Histamine release, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> which in some cases have been life threatening and fatal.  Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see <span class="Bold"><a href="#a48a9215-2f2b-4f8b-bf5d-863e08606306">WARNINGS</a><span class="Italics"> </span></span>and <span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span>).  There are rare reports of <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> following administration of cisatracurium in children.  These reported adverse events were not serious and their etiology could not be established with certainty.</p>
<p><span class="Bold">Musculoskeletal</span></p>
<p>Prolonged neuromuscular block, inadequate neuromuscular block, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="d820e7ec-738d-4f86-89cb-99667146126b"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.  The primary treatment is maintenance of a patent airway and controlled ventilation until recovery of normal neuromuscular function is assured.  Once recovery from neuromuscular block begins, further recovery may be facilitated by administration of an anticholinesterase agent (e.g., neostigmine, edrophonium) in conjunction with an appropriate anticholinergic agent (see <span class="Italics"><span class="Italics"><span class="Bold"><a href="#b78f33b3-5811-40d1-8947-8f81922dd7ae">Antagonism of Neuromuscular Block</a> </span></span></span>below).</p>
<div class="Section" data-sectionCode="34088-5">
<a name="b78f33b3-5811-40d1-8947-8f81922dd7ae"></a><a name="section-9.1"></a><p></p>
<h2>Antagonism of Neuromuscular Block</h2>
<p class="First">ANTAGONISTS (SUCH AS NEOSTIGMINE AND EDROPHONIUM) SHOULD NOT BE ADMINISTERED WHEN COMPLETE NEUROMUSCULAR BLOCK IS EVIDENT OR SUSPECTED.  THE USE OF A PERIPHERAL NERVE STIMULATOR TO EVALUATE RECOVERY AND ANTAGONISM OF NEUROMUSCULAR BLOCK IS RECOMMENDED.</p>
<p>Administration of 0.04 to 0.07 mg/kg neostigmine at approximately 10% recovery from neuromuscular block (range: 0 to 15%) produced 95% recovery of the <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitch</span> response and a T<span class="Sub">4</span>:T<span class="Sub">1</span> ratio ≥ 70% in an average of 9 to 10 minutes.  The times from 25% recovery of the <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitch</span> response to a T<span class="Sub">4</span>:T<span class="Sub">1</span> ratio ≥ 70% following these doses of neostigmine averaged 7 minutes.  The mean 25% to 75% recovery index following reversal was 3 to 4 minutes.</p>
<p>Administration of 1 mg/kg edrophonium at approximately 25% recovery from neuromuscular block (range: 16% to 30%) produced 95% recovery and a T<span class="Sub">4</span>:T<span class="Sub">1</span> ratio ≥ 70% in an average of 3 to 5 minutes. </p>
<p>Patients administered antagonists should be evaluated for evidence of adequate clinical recovery (e.g., 5-second head lift and grip strength). Ventilation must be supported until no longer required. </p>
<p>The onset of antagonism may be delayed in the presence of debilitation, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">carcinomatosis</span>, and the concomitant use of certain broad spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular block or separately cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (see <span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span><span class="Bold">,</span>  <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#be38982d-712d-45a6-a465-3c5407e74175">Drug Interactions</a></span></span></span></span>).  Under such circumstances the management is the same as that of prolonged neuromuscular block (see <span class="Bold"><span class="Bold"><a href="#d820e7ec-738d-4f86-89cb-99667146126b">OVERDOSAGE</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="bac0e4e2-ed66-4d4a-895d-fc2e7ade8e65"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">NOTE: CONTAINS BENZYL ALCOHOL (see <span class="Bold"><a href="#a48a9215-2f2b-4f8b-bf5d-863e08606306">WARNINGS</a></span> and <span class="Bold"><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span><span class="Bold">,</span>  <span class="Bold"><span class="Italics"><span class="Italics"><span class="Bold"><a href="#f28d2edc-681b-4f6a-8cf3-9c67db2f89a4">Pediatric Use</a></span></span></span></span>). </p>
<p><span class="Bold">CISATRACURIUM BESYLATE INJECTION SHOULD ONLY BE ADMINISTERED INTRAVENOUSLY.</span></p>
<br><p><span class="Bold">The dosage information provided below is intended as a guide only.  Doses of Cisatracurium should be individualized (see </span><span class="Bold"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">CLINICAL PHARMACOLOGY</a></span><span class="Italics"><span class="Bold">, </span></span><span class="Italics"><span class="Bold"><a href="#e8946647-8fa3-4a0b-96f9-7a2da2a5ff8b">Individualization of Dosages</a></span></span><span class="Bold">). The use of a peripheral nerve stimulator will permit the most advantageous use of cisatracurium, minimize the possibility of overdosage or underdosage, and assist in the evaluation of recovery.</span></p>
<br><div class="Section" data-sectionCode="34068-7">
<a name="e474078a-f56f-4231-8992-14cae2972c10"></a><a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First"><span class="Bold">Initial Doses</span></p>
<p>One of two intubating doses of cisatracurium may be chosen, based on the desired time to tracheal intubation and the anticipated length of surgery.  In addition to the dose of neuromuscular blocking agent, the presence of co-induction agents (e.g., fentanyl and midazolam) and the depth of anesthesia are factors that can influence intubation conditions.  Doses of 0.15 (3 x ED<span class="Sub">95</span>) and 0.2 (4 x ED<span class="Sub">95</span>) mg/kg cisatracurium, as components of a propofol/nitrous oxide/oxygen induction-intubation technique, may produce generally GOOD or EXCELLENT conditions for intubation in 2 and 1.5 minutes, respectively.  Similar intubation conditions may be expected when these doses of cisatracurium are administered as components of a thiopental/nitrous oxide/oxygen induction-intubation technique.  In two intubation studies using thiopental or propofol and midazolam and fentanyl as co-induction agents, EXCELLENT intubation conditions were most frequently achieved with the 0.2 mg/kg compared to 0.15 mg/kg dose of cisatracurium.  The clinically effective durations of action for 0.15 and 0.2 mg/kg cisatracurium during propofol anesthesia are 55 minutes (range: 44 to 74 minutes) and 61 minutes (range: 41 to 81 minutes), respectively.  Lower doses may result in a longer time for the development of satisfactory intubation conditions.  Doses up to 8 x ED<span class="Sub">95</span> cisatracurium have been safely administered to healthy adult patients and patients with serious cardiovascular disease.  These larger doses are associated with longer clinically effective durations of action (see <span class="Bold"><a href="#f06a906f-80e7-40bf-a494-81eb1b8a5edf">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>Because slower times to onset of complete neuromuscular block were observed in elderly patients and patients with renal dysfunction, extending the interval between administration of cisatracurium and the intubation attempt for these patients may be required to achieve adequate intubation conditions.</p>
<p>A dose of 0.03 mg/kg cisatracurium is recommended for maintenance of neuromuscular block during prolonged surgical procedures.  Maintenance doses of 0.03 mg/kg each sustain neuromuscular block for approximately 20 minutes.  Maintenance dosing is generally required 40 to 50 minutes following an initial dose of 0.15 mg/kg cisatracurium and 50 to 60 minutes following an initial dose of 0.2 mg/kg cisatracurium, but the need for maintenance doses should be determined by clinical criteria.  For shorter or longer durations of action, smaller or larger maintenance doses may be administered.</p>
<p>Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC (Minimum Alveolar Concentration) may prolong the clinically effective duration of action of initial and maintenance doses.  The magnitude of these effects may depend on the duration of administration of the volatile agents.  Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of cisatracurium and therefore, no adjustment to the initial dose should be necessary when cisatracurium is administered shortly after initiation of volatile agents.  In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing or lower maintenance doses of cisatracurium may be necessary.  No adjustments to the initial dose of cisatracurium are required when used in patients receiving propofol anesthesia.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ec9dd954-804b-400e-be50-4cab446a9163"></a><a name="section-10.2"></a><p></p>
<h2>Children</h2>
<p class="First"><span class="Bold">Initial Doses</span></p>
<p>The recommended dose of cisatracurium for children 2 to 12 years of age is 0.1 to 0.15 mg/kg administered over 5 to 10 seconds during either halothane or opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, 0.1 mg/kg cisatracurium produces maximum neuromuscular block in an average of 2.8 minutes (range: 1.8 to 6.7 minutes) and clinically effective block for 28 minutes (range: 21 to 38 minutes).  When administered during stable opioid/nitrous oxide/oxygen anesthesia, 0.15 mg/kg cisatracurium produces maximum neuromuscular block in about 3 minutes (range: 1.5 to 8 minutes) and clinically effective block (time to 25% recovery) for 36 minutes (range: 29 to 46 minutes).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="eb7f6bb3-43ef-46d4-a347-f4547cbea192"></a><a name="section-10.3"></a><p></p>
<h2>Infants</h2>
<p class="First"><span class="Bold">Initial Doses</span></p>
<p>The recommended dose of cisatracurium for intubation of infants 1 month to 23 months is 0.15 mg/kg administered over 5 to 10 seconds during either halothane or opioid anesthesia.  When administered during stable opioid/nitrous oxide/oxygen anesthesia, 0.15 mg/kg cisatracurium produces maximum neuromuscular block in about 2 minutes (range: 1.3 to 3.4 minutes) and clinically effective block (time to 25% recovery) for about 43 minutes (range: 34 to 58 minutes).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ff775980-d2ee-4b37-b1ad-967b1ccb83c0"></a><a name="section-10.4"></a><p></p>
<h2>Use by Continuous Infusion</h2>
<p class="First"><span class="Bold">Infusion in the Operating Room (OR)</span>  <br> </p>
<br><p>After administration of an initial bolus dose of cisatracurium, a diluted solution of cisatracurium can be administered by continuous infusion to adults and children aged 2 or more years for maintenance of neuromuscular block during extended surgical procedures.  Infusion of cisatracurium should be individualized for each patient.  The rate of administration should be adjusted according to the patient's response as determined by peripheral nerve stimulation.  Accurate dosing is best achieved using a precision infusion device.</p>
<br><p>Infusion of cisatracurium should be initiated only after early evidence of spontaneous recovery from the initial bolus dose.  An initial infusion rate of 3 mcg/kg/min may be required to rapidly counteract the spontaneous recovery of neuromuscular function.  Thereafter, a rate of 1 to 2 mcg/kg/min should be adequate to maintain continuous neuromuscular block in the range of 89% to 99% in most pediatric and adult patients under opioid/nitrous oxide/oxygen anesthesia. </p>
<br><p>Reduction of the infusion rate by up to 30% to 40% should be considered when cisatracurium is administered during stable isoflurane or enflurane anesthesia (administered with nitrous oxide/oxygen at the 1.25 MAC level).  Greater reductions in the infusion rate of cisatracurium may be required with longer durations of administration of isoflurane or enflurane.</p>
<br><p>The rate of infusion of atracurium required to maintain adequate surgical relaxation in patients undergoing coronary artery bypass surgery with induced <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> (25° to 28°C) is approximately half the rate required during normothermia.  Based on the structural similarity between cisatracurium and atracurium, a similar effect on the infusion rate of cisatracurium may be expected.</p>
<br><p>Spontaneous recovery from neuromuscular block following discontinuation of infusion of cisatracurium may be expected to proceed at a rate comparable to that following administration of a single bolus dose.</p>
<br><p><span class="Bold">Infusion in the Intensive Care Unit (ICU)</span></p>
<br><p>The principles for infusion of cisatracurium in the OR are also applicable to use in the ICU.  An infusion rate of approximately 3 mcg/kg/min (range: 0.5 to 10.2 mcg/kg/min) should provide adequate neuromuscular block in adult patients in the ICU.  There may be wide interpatient variability in dosage requirements and these may increase or decrease with time (see<span class="Bold"><span class="Italics"> </span><a href="#bfe12ce5-08e7-4d80-b276-03138f9637e3">PRECAUTIONS</a></span><span class="Bold"><span class="Italics">, </span><span class="Italics"><a href="#a81ab4a1-b219-4bc3-a1a3-e28b655ec323">Long-Term Use in the Intensive Care Unit [ICU]</a></span></span>).  Following recovery from neuromuscular block, readministration of a bolus dose may be necessary to quickly re-establish neuromuscular block prior to reinstitution of the infusion.</p>
<br><p><span class="Bold">Infusion Rate Tables</span></p>
<br><p>The amount of infusion solution required per minute will depend upon the concentration of cisatracurium in the infusion solution, the desired dose of cisatracurium, and the patient's weight.  The contribution of the infusion solution to the fluid requirements of the patient also must be considered. Tables 10 and 11 provide guidelines for delivery, in mL/hr (equivalent to microdrops/minute when 60 microdrops = 1 mL), of cisatracurium solutions in concentrations of 0.1 mg/mL (10 mg/100 mL) or 0.4 mg/mL (40 mg/100 mL).</p>
<br><p><span class="Bold">Table 10. Infusion Rates of Cisatracurium for Maintenance of Neuromuscular Block During Opioid/Nitrous Oxide/Oxygen Anesthesia for a Concentration of</span><span class="Bold"> 0.1 mg/mL</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="right" colspan="6" valign="top"> <br><span class="Bold">Drug Delivery Rate (mcg/kg/min)</span><br> <br><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">1</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">1.5</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">2</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">3</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">5</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Patient Weight (kg)</span><br> <br><br>
</td>
<td class="Rrule" align="center" colspan="5" valign="top"> <br><span class="Bold">Infusion Delivery Rate (mL/hr)</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>10<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>6<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>9<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>12<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>18<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>30<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>45<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>27<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>41<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>54<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>81<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>135<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>70<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>42<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>63<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>84<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>126<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>210<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> <br>100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>60<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>90<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>120<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>180<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>300<br> <br><br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">Table 11. Infusion Rates of Cisatracurium for Maintenance of Neuromuscular Block During Opioid/Nitrous Oxide/Oxygen Anesthesia for a Concentration of</span><span class="Bold"> 0.4 mg/mL</span></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="right" colspan="6" valign="top"> <br><span class="Bold">Drug Delivery Rate (mcg/kg/min)</span><br> <br><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">1</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">1.5</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">2</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">3</span><br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">5</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Patient Weight (kg)</span><br> <br><br>
</td>
<td class="Rrule" align="center" colspan="5" valign="top"> <br><span class="Bold">Infusion Delivery Rate (mL/hr)</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>10<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>1.5<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>2.3<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>3<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>4.5<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>7.5<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>45<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>6.8<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>10.1<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>13.5<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>20.3<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>33.8<br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>70<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>10.5<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>15.8<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>21<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>31.5<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>52.5<br> <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> <br>100<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>15<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>22.5<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>30<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>45<br> <br><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>75<br> <br><br>
</td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f9330db6-8315-4991-b0e3-8af800c258f0"></a><a name="section-10.5"></a><p></p>
<h2>Cisatracurium Besylate Injection Compatibility and Admixtures</h2>
<p class="First"><span class="Bold">Y-site Administration</span></p>
<p>Cisatracurium Besylate Injection is acidic (pH = 3.25 to 3.65) and may not be compatible with alkaline solution having a pH greater than 8.5 (e.g., barbiturate solutions).</p>
<p>Studies have shown that Cisatracurium Besylate Injection is compatible with:</p>
<ul class="Disc">
<li>5% Dextrose Injection, USP</li>
<li>0.9% Sodium Chloride Injection, USP </li>
<li>5% Dextrose and 0.9% Sodium Chloride Injection, USP </li>
<li>SUFENTA<span class="Sup">® </span>(sufentanil citrate) Injection, diluted as directed </li>
<li>ALFENTA<span class="Sup">® </span>(alfentanil hydrochloride) Injection, diluted as directed </li>
<li>SUBLIMAZE<span class="Sup">® </span>(fentanyl citrate) Injection, diluted as directed </li>
<li>VERSED<span class="Sup">® </span>(midazolam hydrochloride) Injection, diluted as directed </li>
<li>Droperidol Injection, diluted as directed </li>
</ul>
<p>Cisatracurium Besylate Injection is not compatible with DIPRIVAN<span class="Sup">® </span>(propofol) Injection or TORADOL<span class="Sup">® </span>(ketorolac) Injection for Y-site administration.  Studies of other parenteral products have not been conducted. </p>
<p><span class="Bold">Dilution Stability </span></p>
<p>Cisatracurium Besylate Injection diluted in 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP; or 5% Dextrose and 0.9% Sodium Chloride Injection, USP to 0.1 mg/mL may be stored either under refrigeration or at room temperature for 24 hours without significant loss of potency.  Dilutions to 0.1 mg/mL or 0.2 mg/mL in 5% Dextrose and Lactated Ringer's Injection may be stored under refrigeration for 24 hours. </p>
<p>Cisatracurium Besylate Injection should not be diluted in Lactated Ringer's Injection, USP due to chemical instability. </p>
<p>NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.  Solutions which are not clear, or contain visible particulates, should not be used.  Cisatracurium Besylate Injection is a colorless to slightly yellow or greenish-yellow solution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="e52d5247-6ebb-4984-9d05-b2201674a41e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Cisatracurium Besylate Injection is supplied as:</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="396"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Product</span><br><span class="Bold">No. </span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">NDC</span><br><span class="Bold">No. </span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Strength</span>           <br>
</td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">416005<br>
</td>
<td class="Rrule" valign="top">63323-416-05<br>
</td>
<td class="Rrule" valign="top">10 mg/5 mL<br>            (2  mg/mL)<br>
</td>
<td class="Rrule" valign="top">5 mL single use vials, packaged individually in a carton of 10. <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">417010<br>
</td>
<td class="Rrule" valign="top">63323-417-10<br>
</td>
<td class="Rrule" valign="top">20 mg/10 mL<br>            (2 mg/mL)<br>
</td>
<td class="Rrule" valign="top">10 mL multiple dose vials, packaged individually in a carton of 10.<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">NOTE: </span>10 mL Multiple dose Vials contain 0.9% w/v benzyl alcohol as a preservative (see <span class="Bold"><a href="#a48a9215-2f2b-4f8b-bf5d-863e08606306">WARNINGS</a></span> concerning newborn infants).</p>
<br><br><br><p>Cisatracurium Besylate Injection is supplied as:</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="396"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Product</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">NDC</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Strength            </span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">416020<br>
</td>
<td class="Rrule" valign="top">63323-418-20<br>
</td>
<td class="Rrule" valign="top">200 mg/20 mL<br>            (10 mg/mL)<br>
</td>
<td class="Rrule" valign="top">20 mL single use vials, packaged individually in a carton of 10.<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">Intended only for use in the ICU.</span></p>
<br><div class="Section" data-sectionCode="34069-5">
<a name="fbf11761-1315-48ff-86a5-3cbbaf59d7af"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Cisatracurium Besylate Injection should be refrigerated at 2° to 8°C (36° to 46°F) in the carton to preserve potency.  Protect from light.  DO NOT FREEZE.  Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use Cisatracurium Besylate Injection within 21 days even if rerefrigerated.</p>
<p>The container closure is not made with natural rubber latex.</p>
<p>The brand names mentioned in this document are the trademarks of their respective owners.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bb05257b-8382-4243-a32e-c39dd7a5f8b3"></a><a name="section-12"></a><p></p>
<p class="First"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=fk-address.jpg"><br>451248A</p>
<p>Revised: March 2015</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="a03a5d3f-bd51-4fec-aa4d-e7385fa681d4"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY- Cisatracurium 20 mL Single Use Vial Label</span></p>
<p><span class="Bold">Cisatracurium Besylate Injection</span></p>
<p><span class="Bold">200 mg per 20 mL*   (10 mg per mL)</span></p>
<p>For ICU use only.<br>For intravenous injection.</p>
<p>Preservative free.</p>
<p><span class="Bold">20 mL</span><br>Single Use Vial</p>
<p>Rx only<br><img alt="vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=416020-vial.jpg"></p>
<p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY- Cisatracurium 20 mL Single Use Vial Carton Panel</span></p>
<p><span class="Bold">Cisatracurium Besylate Injection</span></p>
<p><span class="Bold">200 mg per 20 mL*  (10 mg per mL)</span></p>
<p>For ICU use only.  </p>
<p>Warning: Paralyzing Agent.  Causes <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory Arrest</span>.<br>Facilities must be immediately available for artifical<br>respiration.<br>For intravenous injection.</p>
<p>Preservative free.</p>
<p><span class="Bold">10 x 20 mL </span></p>
<p>Single Use Vials</p>
<p>Rx only</p>
<p><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=416020-carton.jpg"> </p>
<p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY- Cisatracurium 5 mL Single Use Vial Label</span></p>
<p><span class="Bold">Cisatracurium Besylate Injection</span></p>
<p><span class="Bold">10 mg (base) per 5 mL (2 mg per mL)</span></p>
<p>For intravenous injection.<br>Preservative free.</p>
<p><span class="Bold">5 mL <br></span>Single Use Vial </p>
<p>Rx only</p>
<p><img alt="416005" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=416005-vial.jpg"> </p>
<p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY- Cisatracurium 5 mL Single Use Vial Carton Panel</span></p>
<p><span class="Bold">Cisatracurium Besylate Injection</span></p>
<p><span class="Bold">10 mg per 5 mL* (2 mg per mL)<br></span>Warning: Paralyzing Agent.  Causes <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory Arrest</span>.<br>Facilities must be immediately available for artifical<br>respiration.</p>
<p>For intravenous injection.<br>Preservative free.</p>
<p><span class="Bold">10 x 5 mL </span></p>
<p>Single Use Vials</p>
<p>Rx only</p>
<p><span class="Bold"><img alt="416005 carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=416005-carton.jpg"><br>PACKAGE LABEL- PRINCIPAL DISPLAY- Cisatracurium 10 mL Multiple Dose Vial Label</span></p>
<p><span class="Bold">Cisatracurium Besylate Injection</span></p>
<p><span class="Bold">20 mg per 10 mL* (2 mg per mL)</span></p>
<p>For intravenous injection.</p>
<p>0.9% benzyl alcohol added as a preservative.</p>
<p><span class="Bold">10 mL</span> Multiple Dose Vial<br>Rx only</p>
<p><img alt="417010 vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=417010-vial.jpg"> </p>
<p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY- Cisatracurium 10 mL Multiple Dose Vial Carton Panel</span></p>
<p><span class="Bold">Cisatracurium Besylate Injection</span></p>
<p><span class="Bold">20 mg per 10 mL* (2 mg per mL)</span></p>
<p>Warning: Paralyzing Agent.  Causes <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory Arrest</span>.<br>Facilities must be immediately available for artifical<br>respiration.<br>For intravenous injection.<br>0.9% benzyl alcohol added as a preservative.<br><span class="Bold">10 x 10 mL</span></p>
<p>Multiple Dose Vials<br>Rx only<br><img alt="417010 carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda&amp;name=417010-carton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CISATRACURIUM 		
					</strong><br><span class="contentTableReg">cisatracurium besylate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-416</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CISATRACURIUM BESYLATE</strong> (CISATRACURIUM) </td>
<td class="formItem">CISATRACURIUM</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZENESULFONIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-416-05</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203182</td>
<td class="formItem">02/26/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CISATRACURIUM 		
					</strong><br><span class="contentTableReg">cisatracurium besylate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-417</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CISATRACURIUM BESYLATE</strong> (CISATRACURIUM) </td>
<td class="formItem">CISATRACURIUM</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZENESULFONIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-417-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203183</td>
<td class="formItem">02/26/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CISATRACURIUM 		
					</strong><br><span class="contentTableReg">cisatracurium besylate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-418</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CISATRACURIUM BESYLATE</strong> (CISATRACURIUM) </td>
<td class="formItem">CISATRACURIUM</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZENESULFONIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-418-20</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203182</td>
<td class="formItem">02/26/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-416, 63323-417, 63323-418)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a636f0cc-a655-4c63-872a-f7c16d1c5280</div>
<div>Set id: f78a07e2-0d3b-4460-b29e-8c10c90afbda</div>
<div>Version: 2</div>
<div>Effective Time: 20150609</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
